[go: up one dir, main page]

DE60101213D1 - Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid-immunomodulator - Google Patents

Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid-immunomodulator

Info

Publication number
DE60101213D1
DE60101213D1 DE60101213T DE60101213T DE60101213D1 DE 60101213 D1 DE60101213 D1 DE 60101213D1 DE 60101213 T DE60101213 T DE 60101213T DE 60101213 T DE60101213 T DE 60101213T DE 60101213 D1 DE60101213 D1 DE 60101213D1
Authority
DE
Germany
Prior art keywords
fungal
immunomodulator
macrolid
squalen
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60101213T
Other languages
English (en)
Other versions
DE60101213T2 (de
Inventor
Stewart Ryder
Karl Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60101213D1 publication Critical patent/DE60101213D1/de
Publication of DE60101213T2 publication Critical patent/DE60101213T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60101213T 2000-02-18 2001-02-16 Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid-immunomodulator Expired - Fee Related DE60101213T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0003932.1A GB0003932D0 (en) 2000-02-18 2000-02-18 Pharmaceutical compositions
GB0003932 2000-02-18
PCT/EP2001/001744 WO2001060345A2 (en) 2000-02-18 2001-02-16 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator

Publications (2)

Publication Number Publication Date
DE60101213D1 true DE60101213D1 (de) 2003-12-18
DE60101213T2 DE60101213T2 (de) 2004-08-19

Family

ID=9886001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60101213T Expired - Fee Related DE60101213T2 (de) 2000-02-18 2001-02-16 Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid-immunomodulator

Country Status (15)

Country Link
US (1) US6919317B2 (de)
EP (1) EP1255564B1 (de)
JP (1) JP3841682B2 (de)
CN (1) CN100400103C (de)
AT (1) ATE253939T1 (de)
AU (1) AU2001254647A1 (de)
BR (1) BR0108403A (de)
CA (1) CA2399971C (de)
DE (1) DE60101213T2 (de)
DK (1) DK1255564T3 (de)
ES (1) ES2210150T3 (de)
GB (1) GB0003932D0 (de)
PT (1) PT1255564E (de)
TR (1) TR200400227T4 (de)
WO (1) WO2001060345A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
WO2004071510A1 (en) * 2003-02-11 2004-08-26 Cipla Ltd Pharmaceutical composition comprising immunosuppressants for the treatment of dermatophytosis
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US9168224B2 (en) * 2004-04-08 2015-10-27 Meda Pharma Sarl Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
WO2006103638A2 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Topical pharmaceutical compositions of terbinafine and processes for their preparation
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US20090082469A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched terbinafine
US20120277193A1 (en) * 2009-09-21 2012-11-01 President And Fellows Of Harvard College Synergistic Combination Therapy
EP3741367A1 (de) 2019-05-21 2020-11-25 Premark Pharma GmbH Behandlung von augenerkrankungen
EP4687895A1 (de) 2023-04-06 2026-02-11 Premark Pharma GmbH Verwendung von pimecrolimus zur behandlung des trockenen auges bei patienten mit einem hornhautfärbungswert von 4 oder 5 auf der oxford-abstufung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
DE69525957T2 (de) * 1994-10-26 2002-11-14 Novartis Ag Verwendung eines ungesättigten Fettalkohols
GB9509631D0 (en) * 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
WO1999017760A2 (en) * 1997-10-02 1999-04-15 Microcide Pharmaceuticals, Inc. Fungal or mammalian cell efflux pump inhibitors for enhancing susceptibility of the cell to a drug

Also Published As

Publication number Publication date
HK1052633A1 (en) 2003-09-26
US20030100517A1 (en) 2003-05-29
PT1255564E (pt) 2004-03-31
BR0108403A (pt) 2003-03-11
JP2003522783A (ja) 2003-07-29
CN100400103C (zh) 2008-07-09
ES2210150T3 (es) 2004-07-01
US6919317B2 (en) 2005-07-19
DE60101213T2 (de) 2004-08-19
EP1255564B1 (de) 2003-11-12
ATE253939T1 (de) 2003-11-15
JP3841682B2 (ja) 2006-11-01
CN1400909A (zh) 2003-03-05
AU2001254647A1 (en) 2001-08-27
CA2399971A1 (en) 2001-08-23
TR200400227T4 (tr) 2004-04-21
EP1255564A2 (de) 2002-11-13
CA2399971C (en) 2009-10-06
WO2001060345A3 (en) 2002-04-18
WO2001060345A2 (en) 2001-08-23
DK1255564T3 (da) 2004-02-09
GB0003932D0 (en) 2000-04-12

Similar Documents

Publication Publication Date Title
DE60101213D1 (de) Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid-immunomodulator
WO2004006858A3 (en) Compounds, compositions, and methods employing same
TNSN07240A1 (en) Compounds for flaviviridae treatment
TW200507830A (en) Bronchodilating β -agonist compositions and methods
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
TW200621268A (en) Antimicrobial copolymers and uses thereof
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2006136420A3 (en) Methods and means for protecting the skin against pathogenic microorganisms
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
SG162773A1 (en) Flavonoid compounds and uses thereof
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
ATE504308T1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
WO2007014372A3 (en) Compositions and methods for treating bacteria
NO20052362L (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
EP4537828A3 (de) Phospholipidverbindungen und verwendungen davon
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
MXPA05010708A (es) Composicion farmaceutica que comprende un inmunosupresor para utilizarse en el tratamiento de enfermedades de la piel.
EP2348039A3 (de) Zyklische antimikrobielle Peptide
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
EP2332526A3 (de) Kombination eines Renin-Inhibitors mit einem anti-dyslipidämischen Wirkstoff oder einem Wirkstoff gegen Adipositas
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
IL166596A0 (en) Salt of morphine-6-glucoronide
EP2250887A3 (de) Verwendung des nicht antibakterielle Tetrazyklin-analog CMT-1002, und Zubereitungen daraus, zur Behandlung von bakteriellen Exotoxinen
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Ref document number: 1255564

Country of ref document: EP

Effective date: 20110901

R082 Change of representative

Ref document number: 1255564

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE